|
Tops:
ArgenX +15.91%: The Belgian biotech nearly doubled its revenue and boosted net profit from €29 million to €245 million year over year. It plans to advance five molecules to Phase 3 by 2030.
Carvana +10.74%: The used-car retailer continues its remarkable comeback, hitting an all-time high. The company outperformed already ambitious expectations, and its potential growth levers keep fueling the valuation.
Roblox +5.23%: The platform surpassed 100 million daily active users for the first time. The challenge now is attracting an older audience that spends more. Both time spent and spending per user are rising sharply.
BBVA +10.17%: The Spanish bank plans to boost profits and shareholder returns over the 2025-2028 period.
Danone +8.57%: Strong demand in China for infant formula and medical nutrition products helped the group beat second-quarter expectations.
Rolls-Royce +8.98%: The British aerospace engineering group raised its full-year profit outlook on Thursday. Longer engine usage times drove improved profitability.
Société Générale +6.01%: The rebound in retail banking allowed Société Générale to raise its 2025 guidance.
Meta +5.24%: Despite higher capital expenditures in 2025, Meta exceeded Wall Street expectations and raised its targets. AI integration should further boost ad revenues.
Microsoft +2.02%: The Redmond giant impressed the market by disclosing Azure’s annual revenue for the first time: $75 billion, up 39% from Q2 2024. Growth is driven by AI solutions, partnerships with OpenAI, xAI, Meta, and Mistral, and enhancements to Copilot. The stock briefly crossed a $4 trillion market cap.
Flops:
Align -33.59%: The Invisalign leader scrapped its annual growth forecast (3.5–5.5%). That makes it a fifth straight year without growth. Demand is falling as patients delay elective treatments in a tough economy. Align is preparing a restructuring with job cuts, more automation, and a shift to regionalized production to cut costs and limit tariff impacts.
Novo Nordisk -31.7%: The Danish drugmaker tumbled after cutting its annual forecast again—the second downgrade in a few months. Its duopoly with Eli Lilly is tipping in favor of the U.S. firm, whose drugs Zepbound and Mounjaro are outperforming Wegovy and Ozempic. The market also fears looming patent expirations for semaglutide in 2026, a surge in counterfeits, and potential political headwinds in the U.S. One bright spot: FDA approval for Alhemo, designed to prevent or reduce bleeding episodes.
Teleperformance -23.93%: The call center operator was hit hard after weak growth, a 14% drop in net income, and skepticism about returns on its AI investments.
UPS -18.4%: The delivery giant reported slightly weaker-than-expected quarterly results and still refuses to issue full-year guidance. Trade tensions with China, the end of tariff exemptions for small parcels, and a 34.8% drop in Amazon volumes (May–June) are creating heavy pressure. Only the international segment is holding up. To cope, UPS is accelerating restructuring efforts (site closures, massive job cuts) amid a highly uncertain macro environment.
Adidas -15.93%: Despite a strong first half and reaffirmed annual targets, management struck a cautious tone for the coming months. The sportswear brand expects a tougher second half, squeezed by expected U.S. tariff hikes on Vietnamese and Indonesian production (its two main sourcing countries) and a currency headwind of about €300 million.
Ferrari -13.97%: The Italian marque slumped after its half-year results. Revenue missed consensus by just 1%, but its order book remains full for two years. No upgrade to annual guidance, but Ferrari maintains its usual prudence and has levers (accelerated limited-series deliveries, controlled price hikes) to manage growth. The brand operates in a market largely immune to economic cycles and is preparing to launch new models next year.
Amazon -7.21%: Unlike peers Microsoft and Alphabet, its cloud growth fell short of expectations last quarter, and the stock was punished. |
